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Abstract:  
 
Introduction: A model for the cardiovascular and circulatory systems (CVS) has 
previously been validated in silico, as well as in porcine models of pulmonary 
embolism (PE), septic shock, and positive end-expiratory pressure (PEEP) titrations 
at different volemic levels. An accurate CVS system model can be used to monitor 
and diagnose dysfunction and support clinical decisions. This research validates this 
model with respect to inotrope therapy commonly used in circulatory support, prior to 
first human clinical trials. 
 
Method: The model and parameter identification process is used to study the effect 
of different adrenaline doses in healthy and critically ill patients. The hemodynamic 
effects on arterial blood pressures and stroke volume (cardiac index) are simulated in 
the model and adrenaline-specific parameters identified. These parameters are then 
used to capture and predict the future responses to a change in dose and-or over 
time. Results are compared to clinical data from 3 adrenaline published dosing 
studies, comprising a total of N=37 data sets. 
 
Results: All identified parameter trends match clinically expected changes. The 
adrenaline-specific parameters are physiologically relevant. Absolute percentage 
errors for the patient-specific, predicted hemodynamic responses (N=15) are within 
10% compared to clinical data. The adrenaline-specific parameters accurately and 
uniquely capture the impact of inotrope therapy on the CVS, independent of other 
model parameters. 
 
Conclusions: Clinically accurate prediction of the impact of circulatory support 
drugs, such as adrenaline, offers significant clinical potential for this type of model-
based application. Overall, this work represents a further clinical validation of the 
underlying fundamental CVS model and methods, and their use for cardiovascular 
diagnosis and therapy selection in critical care. These results are presented as 
(further) justification for (beginning) human trials of this model-based diagnostic and 
therapeutic approach. 
